StockData
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc. (XLO) stock

XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)

Close on Nov 17, 2026Market cap $43.60MP/E –Yield –

Xilio Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Xilio Therapeutics's enterprise value was -$80.31M on Nov 11, 2026, against -$64.50M a year earlier. Over the last 5 years it ranged from -$104.02M to $132.30M, with a median of -$41.88M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$80.31M–
2025Dec 31, 2025-$70.58M–
2024Dec 31, 2024-$19.28M–
2023Dec 29, 2023-$44.63M–
2022Dec 30, 2022-$60.64M–
2021Dec 31, 2021-$77.72M–

More Xilio Therapeutics figures

See a number that looks wrong?